摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S,S)-2-chloro-N-[2-(2-chloro-acetylamino)cyclohexyl]acetamide | 161105-48-2

中文名称
——
中文别名
——
英文名称
(S,S)-2-chloro-N-[2-(2-chloro-acetylamino)cyclohexyl]acetamide
英文别名
trans-1,2-bis(chloroacetamido)cyclohexane;(+/-)-trans-1,2-Bis(chloroacetamido)cyclohexane;2-chloro-N-[(1S,2S)-2-[(2-chloroacetyl)amino]cyclohexyl]acetamide
(S,S)-2-chloro-N-[2-(2-chloro-acetylamino)cyclohexyl]acetamide化学式
CAS
161105-48-2
化学式
C10H16Cl2N2O2
mdl
——
分子量
267.155
InChiKey
NXWRKAARNQHEEG-YUMQZZPRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    58.2
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    (S,S)-2-chloro-N-[2-(2-chloro-acetylamino)cyclohexyl]acetamide 在 lithium aluminium tetrahydride 、 sodium hydride 作用下, 以 乙二醇二甲醚N,N-二甲基乙酰胺 为溶剂, 反应 44.0h, 生成 2R,3R,8S,9S-bis(cyclohexano)-1,4,7,10,13-pentaazacyclopentadecane
    参考文献:
    名称:
    Toward the Rational Design of Superoxide Dismutase Mimics:  Mechanistic Studies for the Elucidation of Substituent Effects on the Catalytic Activity of Macrocyclic Manganese(II) Complexes
    摘要:
    Two new isomeric bis(trans-fused cyclohexano) substituted 1,4,7,10,13-pentaazacyclopentadecane ligands and their Mn(II) complexes, 3 and 14, have been synthesized, and their activity as superoxide dismutase (SOD) catalysts has been studied. Complex 3 is an excellent SOD catalyst with a second-order rate constant at pH 7.4 of 1.2 x 10(+8) M-1 s(-1). In contrast, the isomeric complex 4 has virtually no detectable catalytic SOD activity, implying the need to understand the effect that the position, number, and stereochemistry of substituents exert on the catalytic rate. The crystal structure of the complex 4 was determined and reveals that the Mn(II) ion is coordinated in a pentagonal bipyramid array of the dye nitrogens of the macrocyclic ligand and capped by two trans-chloro ligands. Crystal data for MnC18H37Cl2N5 are as follows: triclinic at 20 degrees C, space group P-1-C(i)2 (no. 2); a = 9.746(3) Angstrom, b = 12.631(6) Angstrom, c = 11.311(5) Angstrom; alpha = 73.14(4)degrees, beta = 76.39(3)degrees, gamma = 79.98(3)degrees, V = 1287(1) Angstrom(3), and Z = 2 (rho(calc) = 1.279 g/cm(3); mu(2) Mo K-alpha = 6.23 mm(-1)). Mechanistic studies with the complex 3 and the pentamethyl susbstituted complex, 5, including D2O rate studies, are reported and are consistent with the existence of two pathways for the rate-determining electron-transfer from Mn(II) to superoxide: (1) hydrogen atom transfer from a bound water on Mn(IP) to HO2. to yield a Mn(III) hydroxo intermediate and (2) the dissociative pathway in which superoxide anion binds to a vacant coordination site on Mn(II) followed by protonation/oxidation to yield a Mn(III)hydroperoxo species. Subsequent reduction of the intermediate Mn(III) with superoxide anion completes the catalytic cycle. Substituent effects on the rates and relative contribution of the two pathways to the overall rate of SOD activity is ascribed to the propensity of the ligand to fold around Mn(II) forming a pseudo-octahedral complex similar in geometry to the oxidized Mn(III) complex. Folding of the pentaaza macrocyclic ligand is confirmed as a relevant structural motif for this series of Mn(TI) complexes by the X-ray structure determination of the bis(nitrate) derivative of 1, [Mn(C10H25N5)NO3]NO3, which reveals a six-coordinate structure with a folded conformation of the macrocyclic ligand. Crystal data for [Mn(C10H25N5)NO3]NO3: orthorhombic at -100 degrees C, space group P2(1)2(1)2(1); a = 9.457(2) Angstrom, b = 12.758(2) Angstrom, c = 13.834(2) Angstrom, V = 1669.1(5) Angstrom(3), and Z = 4 (rho(calc) = 1.549 g/cm(3)).
    DOI:
    10.1021/ja964271e
  • 作为产物:
    描述:
    (1S,2S)-(+)-1,2-环己二胺氯乙酰氯三乙胺 作用下, 以 1,4-二氧六环 为溶剂, 反应 2.0h, 以70%的产率得到(S,S)-2-chloro-N-[2-(2-chloro-acetylamino)cyclohexyl]acetamide
    参考文献:
    名称:
    Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors
    摘要:
    Ambenonium (1), an old AChE inhibitor, is endowed with an outstanding affinity and a peculiar mechanism of action that, taken together, make it a very promising pharmacological tool for the treatment of Alzheimer's disease (AD). Unfortunately, the bisquaternary structure of 1 prevents its passage through the blood brain barrier. In a search of centrally active ambenonium derivatives, we planned to synthesize tertiary amines of 1, such as 2 and 3. In addition, to add new insights into the binding mechanism of the inhibitor, we designed constrained analogues of ambenonium by incorporating the diamine functions into cyclic moieties (4-12). The biological evaluation of the new compounds has been assessed in vitro against human AChE and BChE. All tertiary amine derivatives resulted more than 1000-fold less potent than 1 and, unlike prototype, did not show any selectivity between the two enzymes. This result, because of recent findings concerning the role of BChE in AD, makes our compounds, endowed with a well-balanced profile of AChE/BChE inhibition, valuable candidates for further development. To better clarify the interactions that account for the high affinity of 1, docking simulations and molecular dynamics studies on the AChE-1 complex were also carried out.
    DOI:
    10.1016/s0014-827x(03)00150-2
点击查看最新优质反应信息

文献信息

  • Methods of preparing manganese complexes of nitrogen-containing
    申请人:Monsanto Company
    公开号:US05610293A1
    公开(公告)日:1997-03-11
    The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: ##STR1## wherein R, R', R.sub.1, R'.sub.1, R.sub.2, R'.sub.2, R.sub.3, R'.sub.3, R.sub.4, R'.sub.4, R.sub.5, R'.sub.5, R.sub.6, R'.sub.6, R.sub.7, R'.sub.7, R.sub.8, R'.sub.8, R.sub.9, and R'.sub.9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.
    本发明涉及超化物歧化酶(SOD)的低分子量模拟物,其化学式如下:##STR1## 其中R、R'、R₁、R'₁、R₂、R'₂、R₃、R'₃、R₄、R'₄、R₅、R'₅、R₆、R'₆、R₇、R'₇、R₈、R'₈、R₉和R'₉以及X、Y、Z和n的定义如本文所述,可用作治疗炎症性疾病状态和紊乱、缺血/再灌注损伤、中风、动脉粥样硬化、高血压和所有其他由化剂引起的组织损伤或损伤的条件。
  • Manganese complexes of nitrogen-containing macrocyclic ligands effective
    申请人:G. D. Searle & Co.
    公开号:US05874421A1
    公开(公告)日:1999-02-23
    The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: ##STR1## wherein R, R', R.sub.1, R'.sub.1, R.sub.2, R'.sub.2, R.sub.3, R'.sub.3, R.sub.4, R'.sub.4, R.sub.5, R'.sub.5, R.sub.6, R'.sub.6, R.sub.7, R'.sub.7, R.sub.8, R'.sub.8, R.sub.9, and R'.sub.9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.
    本发明涉及超化物歧化酶(SOD)的低分子量模拟物,其化学式为:##STR1## 其中R、R'、R₁、R'₁、R₂、R'₂、R₃、R'₃、R₄、R'₄、R₅、R'₅、R₆、R'₆、R₇、R'₇、R₈、R'₈、R₉和R'₉以及X、Y、Z和n的定义如本文所述,可用作治疗炎症性疾病状态和紊乱、缺血/再灌注损伤、中风、动脉粥样硬化、高血压和所有其他由化剂引起的组织损伤或损伤的条件的治疗剂。
  • Tissue distribution properties of technetium-99m-diamide-dimercaptide complexes and potential use as renal radiopharmaceuticals
    作者:Sudhakar Kasina、Alan R. Fritzberg、Dennis L. Johnson、Dennis Eshima
    DOI:10.1021/jm00160a023
    日期:1986.10
    Chelation with 99mTc resulted in single radiochemical products or the expected numbers of stereoisomers. They were purified by high-performance liquid chromatography (HPLC) and evaluated in mice as potential renal tubular function agents. The in vivo properties were sensitive to the presence of functional groups, the positional isomerism of the carboxylate group functionality, and the chelate ring stereochemistry
    合成了一系列新的配体和基于二酰胺二巯基供体基团的99 99m螯合物,作为99 99m 1,2-双(2-代乙酰胺基)乙烷的衍生物,该复合物显示可通过肾小管分泌而排泄。与99mTc螯合可产生单一放射化学产物或预期数量的立体异构体。它们通过高效液相色谱(HPLC)纯化,并在小鼠中评估为潜在的肾小管功能药物。体内性质对官能团的存在,羧酸基团官能团的位置异构以及配体的螯合环立体化学敏感。甲基的存在减慢了肾脏的运输,降低了肾脏的特异性。与中心螯合环的乙烯桥稠合的环己基环减少了肾脏排泄,而芳香环则基本消除了肾脏排泄。观察到缓慢的肝胆清除率是另一种排泄方式。极性基团(例如羟基,羧酸根和羧酰胺)以立体化学依赖性方式增加了肾脏排泄率和特异性。鉴定出1,3-双(2-代乙酰胺基)-2-羟基丙烷,3,4-双(2-代乙酰胺基)丁酸和1,8-二巯基-2,7-二代-3,6-二壬酸的99mTc螯合物为有希
  • New conformationally constrained polyaza macrocycles prepared via the bis(chloroacetamide) method
    作者:Patrick J. Lennon、Hayat Rahman、Karl W. Aston、Susan L. Henke、Dennis P. Riley
    DOI:10.1016/s0040-4039(00)75981-8
    日期:1994.1
    The synthesis of two new series of conformationally constrained polyazamacrocycles featuring polysubstitution at macrocycle ring carbons is described.
    描述了两个新的一系列构象受限的聚杂大环化合物的合成,其特征是在大环环上具有多取代基。
  • Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide
    申请人:MONSANTO COMPANY
    公开号:EP0524161A1
    公开(公告)日:1993-01-20
    The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: wherein R, R′, R₁, R′₁, R₂, R′₂, R₃, R′₃, R₄, R′₄, R₅, R′₅, R₆, R′₆, R₇, R′₇, R₈, R′₈, R₉, and R′₉ and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.
    本发明涉及由式表示的超化物歧化酶(SOD)的低分子量模拟物: 其中 R、R′、R₁、R′₁、R₂、R′₂、R₃、R′₃、R′₄、R′₄、R₅、R′₅、R₆、R′₆、R₇、R′₇、R₈、R₉、R₉ 和 R′₉ 以及 X、Y、Z 和 n 如本文所定义、可用作炎症性疾病和失调、缺血/再灌注损伤、中风、动脉粥样硬化、高血压和所有其他化剂诱发的组织损伤或伤害的治疗剂。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸